MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

MC

448.85

+2.56%↑

SANES

7

+1.91%↑

ALV

343

+0.91%↑

BNP

76.72

+1.68%↑

BBVA

12.965

+1.65%↑

Search

DBV Technologies SA

Închisă

1.546 -0.39

Rezumat

Modificarea prețului

24h

Curent

Minim

1.512

Maxim

1.556

Indicatori cheie

By Trading Economics

Venit

-4.1M

-27M

EPS

-0.251

Marjă de profit

-2,852.369

Angajați

106

EBITDA

-2.2M

-25M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+143.33% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.6M

221M

Deschiderea anterioară

1.94

Închiderea anterioară

1.546

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

DBV Technologies SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 dec. 2024, 23:55 UTC

Acțiuni populare

Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

22 oct. 2024, 21:37 UTC

Principalele dinamici ale pieței

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

Comparație

Modificare preț

DBV Technologies SA Așteptări

Obiectiv de preț

By TipRanks

143.33% sus

Prognoză pe 12 luni

Medie 3.65 EUR  143.33%

Maxim 6 EUR

Minim 1.3 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruDBV Technologies SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

1

Cumpărare

0

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

1.61 / 1.72Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.